Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.46 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722103 | 0.83 | IDO1 (0.65) | IDO1TDP1L3MBTL1NOS3NOS1 | |
| SCHEMBL19473645 | 0.81 | IDO1 (0.63) | IDO1L3MBTL1NOS3NOS1NOS2 | |
| SCHEMBL7081788 | 0.80 | IDO1 (0.61) | IDO1TDP1L3MBTL1NOS3NOS1 | |
| SCHEMBL10066807 | 0.77 | IDO1 (0.58) | IDO1TDP1L3MBTL1NOS3NOS1 | |
| SCHEMBL164097 | 0.77 | IDO1 (0.58) | IDO1TDP1L3MBTL1NOS3NOS1 | |
| SCHEMBL6684302 | 0.77 | IDO1 (0.57) | IDO1TDP1L3MBTL1NOS3NOS1 | |
| SCHEMBL28184258 | 0.75 | TDP1 (0.61) | IDO1TDP1L3MBTL1NOS3NOS1 | |
| SCHEMBL6831249 | 0.74 | IDO1 (0.54) | IDO1TDP1L3MBTL1NOS3NOS1 | |
| SCHEMBL6790276 | 0.74 | TDP1 (0.55) | IDO1TDP1L3MBTL1NOS3NOS1 | |
| SCHEMBL3070200 | 0.73 | IDO1 (0.71) | IDO1TDP1L3MBTL1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9572788-B2 | Cell permeable inhibitors of anaphase promoting complex | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150328214-A1 | CELL PERMEABLE INHIBITORS OF ANAPHASE PROMOTING COMPLEX | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-11-19 | — | — | US | disclosed |
| WO-2012031118-A2 | CELL PERMEABLE INHIBITORS OF ANAPHASE PROMOTING COMPLEX | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328214-A1 | CELL PERMEABLE INHIBITORS OF ANAPHASE PROMOTING COMPLEX | CDC20, BUB1B, BUB1 | IDO1 4055/4885TDP1 993/4885L3MBTL1 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.